臨床試験

SNIFF - Combo INI+EMPA Trial

NCT: NCT05081219 · COMPLETED

NCT識別子NCT05081219

ステータスCOMPLETED

開始日2021-09-14

完了2024-09-17

SponsorWake Forest University Health Sciences (OTHER)

First posted2021-10-18

Last updated2026-10-07

概要

The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin, to correct bioenergetic and vascular dysfunction in adults with preclinical Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI) or early AD.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。